全文获取类型
收费全文 | 10354篇 |
免费 | 502篇 |
国内免费 | 123篇 |
专业分类
耳鼻咽喉 | 52篇 |
儿科学 | 227篇 |
妇产科学 | 305篇 |
基础医学 | 1112篇 |
口腔科学 | 166篇 |
临床医学 | 764篇 |
内科学 | 2660篇 |
皮肤病学 | 277篇 |
神经病学 | 974篇 |
特种医学 | 415篇 |
外科学 | 1867篇 |
综合类 | 26篇 |
一般理论 | 1篇 |
预防医学 | 336篇 |
眼科学 | 140篇 |
药学 | 668篇 |
中国医学 | 27篇 |
肿瘤学 | 962篇 |
出版年
2024年 | 16篇 |
2023年 | 77篇 |
2022年 | 235篇 |
2021年 | 286篇 |
2020年 | 185篇 |
2019年 | 220篇 |
2018年 | 290篇 |
2017年 | 198篇 |
2016年 | 271篇 |
2015年 | 335篇 |
2014年 | 428篇 |
2013年 | 559篇 |
2012年 | 856篇 |
2011年 | 823篇 |
2010年 | 543篇 |
2009年 | 442篇 |
2008年 | 721篇 |
2007年 | 722篇 |
2006年 | 645篇 |
2005年 | 645篇 |
2004年 | 605篇 |
2003年 | 490篇 |
2002年 | 463篇 |
2001年 | 60篇 |
2000年 | 59篇 |
1999年 | 56篇 |
1998年 | 95篇 |
1997年 | 56篇 |
1996年 | 60篇 |
1995年 | 56篇 |
1994年 | 60篇 |
1993年 | 43篇 |
1992年 | 41篇 |
1991年 | 42篇 |
1990年 | 39篇 |
1989年 | 24篇 |
1988年 | 25篇 |
1987年 | 19篇 |
1986年 | 15篇 |
1985年 | 14篇 |
1984年 | 26篇 |
1983年 | 23篇 |
1982年 | 11篇 |
1981年 | 10篇 |
1980年 | 12篇 |
1979年 | 6篇 |
1978年 | 10篇 |
1977年 | 9篇 |
1975年 | 6篇 |
1974年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 109 毫秒
81.
Giuseppe Caliendo Ferdinando Fiorino Paolo Grieco Elisa Perissutti Vincenzo Santagada Rosaria Meli Giuseppina Mattace Raso Angelina Zanesco Gilberto De Nucci 《European journal of medicinal chemistry》1999,34(12):1043
Two sets of benzotriazinone and benzoyltriazole derivatives were prepared and tested for local anaesthetic activity in comparison with lidocaine. Several of the prepared compounds exhibited a fairly good activity comparable or superior to that of lidocaine. The presence of a benzotriazinone or a benzoyltriazole moiety as an aromatic system was quite profitable for both the intensity and duration of activity. The acute toxicity in mice of the four most potent compounds of the series was also assessed. Compound 1b, which has an anaesthetic activity comparable to that of lidocaine, was also characterized by a more favourable therapeutic index. All compounds were tested in vitro to evaluate their negative chronotropic action in isolated rat right atria. 相似文献
82.
G. Scambia F. O. Ranelletti P. Benedetti Panici M. Piantelli G. Bonanno R. de Vincenzo G. Ferrandina L. Pierelli A. Capelli S. Mancuso 《Cancer chemotherapy and pharmacology》1991,28(4):255-258
Summary It has been demonstrated that the flavonoid quercetin (3,3,4,5,7-pentahydroxyflavone; Q) inhibits the growth of several cancer cell lines. There is evidence suggesting that the antiproliferative activity of this substance is mediated by the so-called type II estrogen-binding, site (type II EBS). We looked for the presence of type II EBS and the effect of Q on the proliferation of an Adriamycinresistant estrogen-receptor-negative human breast-cancer cell line (MCF-7 ADRr). By whole-cell assay using estradiol labelled with 6,7-tritium ([3H]-E2) as a tracer, we demonstrated that MCF-7 ADRr cells contain type II EBSs. Competition analysis revealed that diethylstilbestrol (DES) and Q competed with similar potency for [3H]-Es binding to type II EBSs. The antiestrogen tamoxifen (TAM) competed for type II EBSs, albeit to a lesser extent than either DES or Q. Growth experiments demonstrated that Q and DES exerted a dose-dependent inhibition of cell proliferation in the range of concentrations between 10 nM and 10 m, whereas TAM was less effective. Q could also inhibit colony formation in a clonogenic assay. Our results indicate that multidrug-resistant estrogen-receptor-negative MCF-7 cells express, type II EBSs and are sensitive to the inhibitory effect of Q. This substance could be the parent compound of a novel class of anticancer agents. 相似文献
83.
84.
Soluble CD40 ligand plasma levels in lung cancer. 总被引:7,自引:0,他引:7
Mario Roselli Tommaso C Mineo Stefania Basili Francesca Martini Sabrina Mariotti Simona Aloe Girolamo Del Monte Vincenzo Ambrogi Antonella Spila Raffaele Palmirotta Roberta D'Alessandro Giovanni Davì Fiorella Guadagni Patrizia Ferroni 《Clinical cancer research》2004,10(2):610-614
PURPOSE: Tumor-induced platelet activation may cause the release of various cytokines, including CD40 ligand (CD40L). Activation of the CD40/CD40L pathway in human tumors may result in thrombin generation, which is known to be involved in angiogenesis. Thus, we investigated whether soluble (s)CD40L levels are increased in patients with lung cancer as a result of platelet and/or coagulation activation. EXPERIMENTAL DESIGN: Citrated plasma samples were obtained from 120 patients with different stages and histotypes of lung cancer and 60 age- and sex-matched control subjects. sCD40L, sP-selectin (marker of platelet activation), prothrombin fragment 1 + 2, and thrombin-antithrombin III complex levels (both markers of coagulative activation) were measured in all samples. RESULTS: Patients with lung cancer had median sCD40L levels higher than in control subjects (0.46 versus 0.13 ng/ml; P < 0.0001), although correlation with the stage of disease was not evident. Nonetheless, sCD40L levels were significantly higher in squamous cancer compared with adenocarcinoma (0.75 versus 0.27 ng/ml; P < 0.05). Moreover, median sCD40L levels were higher in stage IV compared with nonmetastatic squamous lung cancer (1.02 versus 0.61 ng/ml; P < 0.05). sCD40L levels significantly correlated with sP-selectin (P < 0.001), prothrombin fragment 1 + 2 (P < 0.001), or thrombin-antithrombin III complex (P < 0.05) in squamous lung cancer, but only sP-selectin (P = 0.011) was independently related to sCD40L. CONCLUSIONS: These findings indicate that elevated sCD40L levels can be preferentially found in patients with advanced squamous cancer and provide evidence that increased levels of this cytokine are associated to the occurrence of in vivo platelet activation. 相似文献
85.
Francesco Izzo Paolo Marra Gerardo Beneduce Giuseppe Castello Paolo Vallone Vincenzo De Rosa Franco Cremona C Mark Ensor Frederick W Holtsberg John S Bomalaski Mike A Clark Chaan Ng Steven A Curley 《Journal of clinical oncology》2004,22(10):1815-1822
PURPOSE: Recently, we reported that a large number of human hepatocellular cancer (HCC) cell lines were auxotrophic for arginine. Here we report the results obtained with the amino acid-degrading enzyme arginine deiminase (ADI) conjugated to polyethylene glycol (ADI-SS PEG 20,000 mw) as a means of lowering plasma arginine to treat HCC. The study was a cohort dose-escalation phase I/II study. PATIENTS AND METHODS: Pharmacodynamic studies indicated an ADI-SS PEG 20,000 mw dose level of 160 U/m(2) was sufficient to lower plasma arginine from a resting level of approximately 130 micromol/L to below the level of detection (< 2 micromol/L) for more than 7 days, a dose later defined as the optimal biologic dose. All patients were to receive three cycles at the optimum biologic dose. RESULTS: This therapy was well tolerated, even in patients who had no detectable plasma arginine for 3 continuous months of therapy. Of the 19 patients enrolled, two had a complete response, seven had a partial response, seven had stable disease, and three had progressive disease. The median survival for the 19 patients enrolled on this study was 410 days, with four patients still alive at present (> 680 days). CONCLUSION: Elimination of all detectable plasma arginine in patients with HCC was well tolerated and seemed to be effective in the treatment of some patients with HCC. Further testing of ADI-SS PEG 20,000 mw in a larger population of individuals with HCC as well as other human tumors auxotrophic for arginine is warranted. 相似文献
86.
Roberto Bianco Roberta Caputo Rosa Caputo Vincenzo Damiano Sabino De Placido Corrado Ficorella Sudhir Agrawal A Raffaele Bianco Fortunato Ciardiello Giampaolo Tortora 《Clinical cancer research》2004,10(14):4858-4864
PURPOSE: The epidermal growth factor receptor (EGFR) may play a relevant role in the progression, hormone therapy resistance, and prognosis of prostate cancer patients. Also MDM2, a negative p53 regulator that interacts with retinoblastoma (Rb), E2F, p19(arf) and the ras-mitogen-activated protein kinase(MAPK) cascade plays an important role in prostate cancer progression and prognosis. On the basis of the EGFR and MDM2 role in integrating signaling pathways critical for prostate cancer progression, we investigated whether their selective combined blockade may have a cooperative antitumor effect in prostate cancer. For this purpose, we have used the EGFR tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) and a second generation hybrid oligonucleotide antisense MDM2 (AS-MDM2), respectively. EXPERIMENTAL DESIGN: Gefitinib and AS-MDM2 were administered to hormone-refractory and hormone-dependent human prostate cancer cells in vitro and to mice bearing tumor xenografts, evaluating the effects on growth, apoptosis, and protein expression, in vitro and in vivo. RESULTS: We demonstrated that the combination of gefitinib and AS-MDM2 synergistically inhibits the growth of hormone-independent prostate cancer cells in vitro. This effect is accompanied by the inhibition of MDM2, phosphorylated Akt (pAkt), phosphorylated MAPK (pMAPK), and vascular endothelial growth factor (VEGF) expression and by Rb hypophosphorylation. The combination of the two agents in nude mice bearing the same hormone-independent tumors caused a potent cooperative antitumor effect. Tumor samples analysis confirmed the inhibition of MDM2, pAkt, pMAPK, VEGF, and basic fibroblast growth factor expression. CONCLUSIONS: This study shows that EGFR and MDM2 play a critical role in the growth of prostate cancer, especially hormone-dependent, and that their combined blockade by gefitinib and AS-MDM2 causes a cooperative antitumor effect, supporting the clinical development of this therapeutic strategy. 相似文献
87.
HMGA1 protein overexpression in human breast carcinomas: correlation with ErbB2 expression. 总被引:6,自引:0,他引:6
Gennaro Chiappetta Gerardo Botti Mario Monaco Rosa Pasquinelli Francesca Pentimalli Maurizio Di Bonito Giuseppe D'Aiuto Monica Fedele Rodolfo Iuliano Emiliano A Palmieri Giovanna Maria Pierantoni Vincenzo Giancotti Alfredo Fusco 《Clinical cancer research》2004,10(22):7637-7644
We measured, by immunohistochemistry, HMGA1 protein expression in 212 breast tissue specimens: 6 normal samples, 28 hyperplastic lesions (13 with cellular atypia), 11 fibroadenomas, 10 in situ ductal carcinomas, 144 ductal carcinomas, and 13 lobular carcinomas. HMGA1 was not expressed in normal breast tissue; HMGA1 staining was intense in 40% of hyperplastic lesions with cellular atypia and in 60% of ductal carcinomas and weak in fibroadenomas and in hyperplastic lesions without cellular atypia. Because HMGA1 expression was similar among ductal breast carcinomas with different histologic grading, we evaluated the association between HMGA1 expression and that of other markers of breast carcinoma invasion (estrogen and progesterone receptors, Ki-67 antigen, and ErbB2) in 21 cases of grade 3 breast ductal carcinomas and 7 cases of breast lobular carcinomas. We found that HMGA1 expression tended to be associated only with c-erbB-2 expression (Spearman rho: 0.36; P=0.065). Taken together, these results suggest that HMGA1 expression might be a novel indicator for the diagnosis and prognosis of human breast cancer. 相似文献
88.
Prognostic value of CD40 in adult soft tissue sarcomas. 总被引:4,自引:0,他引:4
Alessandro Ottaiano Anna De Chiara Francesco Perrone Gerardo Botti Flavio Fazioli Vincenzo De Rosa Nicola Mozzillo Vincenzo Ravo Brunello Morrica Ciro Gallo Carmela Pisano Maria Napolitano Paolo Antonio Ascierto Rosario Vincenzo Iaffaioli Gaetano Apice 《Clinical cancer research》2004,10(8):2824-2831
PURPOSE: The purpose is to evaluate the expression of CD40, a membrane protein predominantly expressed on B cells, dendritic cells, and macrophages, in a series of adult soft tissue sarcomas and to test its possible prognostic value. EXPERIMENTAL DESIGN: CD40 expression was studied by immunohistochemistry. Correlations with other baseline characteristics of patients and tumors were analyzed with chi(2) test. The prognostic value was studied with univariable and multivariable analysis adjusted by age, sex, tumor size, grade, location, and distant metastases. RESULTS: Eighty-two patients, between January 1994 and May 2001, were analyzed. Membrane or cytoplasmic staining for CD40 protein was absent in 30% of the tumors but present in <10% of cells in 22 (27%), in 10% to 50% in 23 (28%), and in >50% of cells in 12 (15%) tumors. There was no correlation between CD40 expression and age, sex, size, grade, and location of the primary tumor and distant metastases. With 61 patients (74.4%) progressed and 31 (37.8%) dead, CD40 expression was a significant prognostic factor for disease-free and overall survival at univariable and multivariable analysis. Patients with tumors expressing CD40 in >50% of cells had a dramatically unfavorable prognosis with median disease-free and overall survival of 7 and 17 months, respectively, and hazard ratios of relapse and death as compared with patients with CD40-negative tumors of 2.89 (95% confidence interval: 1.26-6.60) and 6.92 (95% confidence interval: 2.18-22.0), respectively. CONCLUSIONS: These data suggest that expression of CD40 protein in >50% of cells might indicate an unfavorable prognosis in adult soft tissue sarcomas. 相似文献
89.
Vascular endothelial growth factor and p53 expressions in liver and abdominal metastases from colon cancer. 总被引:4,自引:0,他引:4
Stefano Cascinu Francesco Graziano Vincenzo Catalano Sandro Barni Paolo Giordani Anna Maria Baldelli Maria Pia Staccioli Cristina Rossi Angelo Brenna Andrea Valenti Pietro Muretto Giuseppina Catalano 《Tumour biology》2003,24(2):77-81
OBJECTIVE: To determine the relationship between p53 overexpression and vascular endothelial growth factor (VEGF) upregulation in liver and abdominal metastases from colon cancer. The analysis in the two metastatic sites was carried out to evaluate the potential role of microenvironment in the molecular regulation of VEGF. METHODS: Bioptic specimens of liver and abdominal metastases from colon carcinomas were examined by immunohistochemistry for p53 and VEGF expressions. Consecutive cases with assessable tumor tissue were selected. RESULTS: The study population consisted of 24 cases having liver metastases and 34 cases having abdominal metastases. Abdominal metastases showed a higher number of VEGF-positive cases and a higher intensity of VEGF immunoreactivity than liver metastases did (p = 0.01). The combined analysis of p53 and VEGF showed a strong association between the two markers in the 24 liver metastases; 9 cases were VEGF positive/p53 positive and 15 cases were VEGF negative/p53 negative. This relationship was not found in the 34 abdominal metastases, which showed concordance between the two markers in 9 VEGF-positive/p53-positive cases only. CONCLUSIONS: Microenvironment factors like hypoxia may have a predominant role in inducing VEGF expression and they can override the molecular control of p53 on VEGF. 相似文献
90.